Aspen launches once-a-day HIV drug in SA

Organisation: Position: Deadline Date: Location:

South African drug-maker Aspen Pharmacare has launched a triple-combination tablet for the treatment of HIV in the country where the virus is most prevalent, reports Reuters Health. The company’s new Emdolten drug is a once-a-day tablet in the form of dolutegravir, an antiretroviral medication that counters the drug resistance that often develops with older HIV treatments, Aspen said. The drug also contains lamivudine and tenofovir disoproxil fumarate alongside dolutegravir.

The report says in May the South African Health Products Regulatory Authority and the European Medicines Agency issued a warning advising doctors not to prescribe dolutegravir to women seeking to become pregnant. This followed preliminary data from a study in Botswana, which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

The drug is found in the branded medicines Tivicay and Triumeq, which are sold by GlaxoSmithKline’s majority-owned ViiV Healthcare unit.

Aspen, which pioneered the development and manufacture of generic antiretrovirals (ARV) in South Africa, said in the report that using dolutegravir was safe for men, women who are not of child bearing age and child-bearing women using contraceptives, adding that these groups represent more than 70% of HIV patients. “The fact that it (Emdolten) has been registered means that SAHPRA is comfortable that it is safe to take to the public,” Aspen strategic trade executive Stavros Nicolaou said, referring to South African Health Products Regulatory Authority.

The report says the company launched Aspen Stavudine – its first generic ARV drug in August 2003 – at a time when the country was grappling with a high rate of HIV infection.

South Africa has 19% of the global number of people living with HIV, 15% of new infections and 11% of Aids-related deaths, the UNAIDS agency says on its website.

There is no vaccine to prevent HIV/Aids. Current treatments only helping patients to manage the disease, but the fast-mutating virus has proved a challenge to the medical community because it often develops resistance to existing medicines.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.